Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036839 · ClinicalTrials.gov registry record · Phase 2
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT03036839 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 95 participants.
The verdict
NCT03036839, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety, efficacy and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) in adults with chronic HCV infection who are on dialysis for ESRD.
Interventions
- DRUG LDV/SOF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2019-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03036839
The ClinicalTrials.gov registry entry for NCT03036839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LDV/SOF is the first listed.
NCT03036839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03036839 about?
NCT03036839 is a clinical study titled "Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease". The primary objectives of this study are to evaluate the safety, efficacy and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) in adults with chronic HCV infection who are on dialysis for ESRD.
What is the current status of trial NCT03036839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2017-06-27. Estimated completion is 2019-02-14.
What interventions are being tested in trial NCT03036839?
The interventions under investigation include: LDV/SOF (DRUG).
Who is sponsoring clinical trial NCT03036839?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.